{"id":"NCT03391466","sponsor":"Kite, A Gilead Company","briefTitle":"Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma","officialTitle":"A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA-7)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-01-25","primaryCompletion":"2021-03-18","completion":"2024-11-25","firstPosted":"2018-01-05","resultsPosted":"2024-03-07","lastUpdate":"2024-12-24"},"enrollment":359,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)"],"interventions":[{"type":"BIOLOGICAL","name":"Axicabtagene Ciloleucel","otherNames":["KTE-C19","axi-cel","Yescarta Â®"]},{"type":"DRUG","name":"Platinum-containing salvage chemotherapy (eg, R-ICE) followed by high dose therapy (eg, BEAM) and autologous stem cell transplant in responders.","otherNames":[]},{"type":"DRUG","name":"Cyclophosphamide","otherNames":[]},{"type":"DRUG","name":"Fludarabine","otherNames":[]}],"arms":[{"label":"Axicabtagene Ciloleucel Treatment","type":"EXPERIMENTAL"},{"label":"Standard of Care Therapy","type":"ACTIVE_COMPARATOR"}],"summary":"The goal of this clinical study is to assess whether axicabtagene ciloleucel therapy improves the clinical outcome compared with standard of care second-line therapy in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).","primaryOutcome":{"measure":"Event Free Survival (EFS) Per Blinded Central Assessment","timeFrame":"From randomization date up to a median follow-up: 24.9 months","effectByArm":[{"arm":"Axicabtagene Ciloleucel","deltaMin":8.3,"sd":null},{"arm":"Standard of Care Therapy","deltaMin":2,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":12},"locations":{"siteCount":72,"countries":["United States","Australia","Austria","Belgium","Canada","France","Germany","Israel","Italy","Netherlands","Spain","Sweden","Switzerland","United Kingdom"]},"refs":{"pmids":["25113753","26980727","35839452","36646322","34891224","36999993","37272527","39240498","38635762","38557775","38315832","35114155","34922648","34515338","33288485"],"seeAlso":["https://www.gileadclinicaltrials.com/study/?id=KTE-C19-107"]},"adverseEventsSummary":{"seriousAny":{"events":95,"n":170},"commonTop":["Pyrexia","Nausea","Anaemia","Fatigue","Diarrhoea"]}}